News headlines about Ekso Bionics (NASDAQ:EKSO) have trended somewhat negative on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ekso Bionics earned a news impact score of -0.03 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.3682406433782 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s analysis:
- Ekso Bionics’ (EKSO) CEO Jack Peurach on Q4 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Ekso Bionics Reports Fourth Quarter and Year End 2017 Results – GlobeNewswire (press release) (globenewswire.com)
- Ekso Bionics Reports Fourth Quarter and Year End 2017 Results … – GlobeNewswire (press release) (globenewswire.com)
- Robbins Arroyo LLP: Ekso Bionics Holdings, Inc. (EKSO) Misled … – Business Wire (press release) (businesswire.com)
- Ekso Bionics Reports Fourth Quarter and Year End 2017 Results Nasdaq:EKSO (menafn.com)
Shares of Ekso Bionics (NASDAQ EKSO) traded down $0.13 during mid-day trading on Wednesday, reaching $1.58. 448,811 shares of the company’s stock were exchanged, compared to its average volume of 491,542. Ekso Bionics has a 52-week low of $0.99 and a 52-week high of $4.77. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. The firm has a market cap of $102.97, a price-to-earnings ratio of -1.70 and a beta of 1.34.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-ekso-bionics-ekso-stock-price/1926332.html.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.